Clinical Trials Directory

Trials / Sponsors / Shanghai BDgene Co., Ltd.

Shanghai BDgene Co., Ltd.

Industry · 10 registered clinical trials — 6 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL
High-grade Squamous Intraepithelial Lesions (HSIL)
N/A2025-09-01
RecruitingA Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Kera
Herpes Simplex Virus Type I Stromal Keratitis
Phase 22025-04-28
RecruitingCRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
Primary Open Angle Glaucoma
N/A2024-06-10
RecruitingA Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
β-thalassemia
Phase 12024-01-05
RecruitingSafety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-t
β-thalassemia
N/A2023-09-15
Active Not RecruitingA Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal
Herpes Simplex Virus Type I Stromal Keratitis
Phase 12023-09-04
RecruitingSafety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thal
β-thalassemia Major
N/A2023-08-10
Active Not RecruitingVEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
EARLY_Phase 12021-11-25
CompletedA Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants
Hematologic Diseases
N/A2021-07-10
CompletedSafety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis
Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection
N/A2020-11-04